Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

A HTS for HPK1 inhibitors using a new Automation Platform and the Sygnature LeadFinder Library

Abstract

At Sygnature Discovery, our new custom built, internal High Throughput Screening (HTS) system has been designed and built using industry-leading vendors to allow us to expand our screening capabilities and ensure rapid and precise identification of hit chemical series suitable for progression into lead discovery.

To demonstrate the operational performance of our HTS system we performed a primary screen of our 150,000 compound LeadFinder library to identify inhibitors of HPK1, an interesting and druggable immuno-oncology drug target. Herein, we describe the development of a suitable, biologically relevant assay which has been fully adapted and tested for the rigours of HTS.

Download Poster

Poster download form with organisation field